SGLT2 inhibitors:glucuretic treatment for type 2 diabetes

Bailey, Clifford J. and Day, Caroline (2010). SGLT2 inhibitors:glucuretic treatment for type 2 diabetes. British Journal of Diabetes and Vascular Disease, 10 (4), pp. 193-199.

Abstract

Sodium glucose co-transporter-2 (SGLT2) inhibitors offer a novel approach to treat diabetes by reducing hyperglycaemia via increased glucosuria. This approach reduces renal glucose reabsorption in the proximal renal tubules providing an insulin-independent mechanism to lower blood glucose. The glucuretics are advanced in clinical development and dapagliflozin has received most extensive study. Once daily dapaglifolozin as monotherapy or as add-on to metformin for 12-24 weeks in type 2 diabetic patients (baseline HbA 8-9%) reduced HbA by about 0.5-1%, accompanied by weight loss (2-3 kg) and without significant risk of hypoglycaemia. Dapagliflozin has reduced insulin requirement and improved glycaemic control without weight gain in insulin-treated patients. A mild osmotic diuresis associated with glucuretic therapy may account for a small increase in haematocrit (1-2%) and reduced blood pressure (2-5 mmHg). Dehydration and altered electrolyte balance have not been encountered. Urinary tract and genital infections increased in most studies with dapagliflozin, but were typically mild - resolving with selfmedication or standard intervention. Thus glucuretics provide a novel insulin-independent approach for control of hyperglycaemia which does not incur hypoglycaemia, promotes weight loss, may reduce blood pressure and offers compatibility with other glucose-lowering agents.

Publication DOI: https://doi.org/10.1177/1474651410377832
Divisions: Life & Health Sciences > Biosciences
Uncontrolled Keywords: dapagliflozin diabetes,flozins,glucuretics,hypoglycaemic
Published Date: 2010-07

Download

Full text not available from this repository.

Export / Share Citation


Statistics

Additional statistics for this record